Hemispherx hopes new 'PDUFA V' measure will save Ampligen
This article was originally published in Scrip
Executive Summary
With the fate of Hemispherx Biopharma's chronic fatigue syndrome (CFS) therapy Ampligen once again in the hands of the US FDA, the Philadelphia biotech made no bones about warning investors on 1 August that there were no assurances the data in the company's response would provide adequate evidence of efficacy.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.